These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31133280)

  • 1. The North Carolina Experience with Mucopolysaccharidosis Type I Newborn Screening.
    Taylor JL; Clinard K; Powell CM; Rehder C; Young SP; Bali D; Beckloff SE; Gehtland LM; Kemper AR; Lee S; Millington D; Patel HS; Shone SM; Woodell C; Zimmerman SJ; Bailey DB; Muenzer J
    J Pediatr; 2019 Aug; 211():193-200.e2. PubMed ID: 31133280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combined use of enzyme activity and metabolite assays as a strategy for newborn screening of mucopolysaccharidosis type I.
    Polo G; Gueraldi D; Giuliani A; Rubert L; Cazzorla C; Salviati L; Marzollo A; Biffi A; Burlina AP; Burlina AB
    Clin Chem Lab Med; 2020 Nov; 58(12):2063-2072. PubMed ID: 32432561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First Three Years' Experience of Mucopolysaccharidosis Type-I Newborn Screening in California.
    Fillman T; Matteson J; Tang H; Mathur D; Zahedi R; Sen I; Bishop T; Neogi P; Feuchtbaum L; Olney RS; Sciortino S
    J Pediatr; 2023 Dec; 263():113644. PubMed ID: 37516270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan.
    Chuang CK; Lin HY; Wang TJ; Huang YH; Chan MJ; Liao HC; Lo YT; Wang LY; Tu RY; Fang YY; Chen TL; Ho HC; Chiang CC; Lin SP
    Orphanet J Rare Dis; 2018 May; 13(1):84. PubMed ID: 29801497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosing lysosomal storage disorders: mucopolysaccharidosis type I.
    Johnson BA; Dajnoki A; Bodamer OA
    Curr Protoc Hum Genet; 2015 Jan; 84():17.17.1-17.17.8. PubMed ID: 25599668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newborn screening of mucopolysaccharidosis type I.
    Burlina AB; Gragnaniello V
    Crit Rev Clin Lab Sci; 2022 Jun; 59(4):257-277. PubMed ID: 35037566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taiwan National Newborn Screening Program by Tandem Mass Spectrometry for Mucopolysaccharidoses Types I, II, and VI.
    Chan MJ; Liao HC; Gelb MH; Chuang CK; Liu MY; Chen HJ; Kao SM; Lin HY; Huang YH; Kumar AB; Chennamaneni NK; Pendem N; Lin SP; Chiang CC
    J Pediatr; 2019 Feb; 205():176-182. PubMed ID: 30409495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Report of Five Years of Experience in Neonatal Screening for Mucopolysaccharidosis Type I and Review of the Literature.
    Gragnaniello V; Gueraldi D; Rubert L; Manzoni F; Cazzorla C; Giuliani A; Polo G; Salviati L; Burlina A
    Int J Neonatal Screen; 2020 Nov; 6(4):. PubMed ID: 33147872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan.
    Lin SP; Lin HY; Wang TJ; Chang CY; Lin CH; Huang SF; Tsai CC; Liu HL; Keutzer J; Chuang CK
    Orphanet J Rare Dis; 2013 Sep; 8():147. PubMed ID: 24053568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I.
    Peck DS; Lacey JM; White AL; Pino G; Studinski AL; Fisher R; Ahmad A; Spencer L; Viall S; Shallow N; Siemon A; Hamm JA; Murray BK; Jones KL; Gavrilov D; Oglesbee D; Raymond K; Matern D; Rinaldo P; Tortorelli S
    Int J Neonatal Screen; 2020 Mar; 6(1):10. PubMed ID: 33073008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newborn screening in mucopolysaccharidoses.
    Donati MA; Pasquini E; Spada M; Polo G; Burlina A
    Ital J Pediatr; 2018 Nov; 44(Suppl 2):126. PubMed ID: 30442156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzymatic testing for mucopolysaccharidosis type I in Kuwaiti newborns: a preliminary study toward newborn screening.
    Alsharhan H; Haider MZ; Qadoura B; Ayed M; Dhaunsi GS; Alkandari H
    Front Pediatr; 2024; 12():1376053. PubMed ID: 39077064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of X-Linked Adrenoleukodystrophy Newborn Screening in North Carolina.
    Lee S; Clinard K; Young SP; Rehder CW; Fan Z; Calikoglu AS; Bali DS; Bailey DB; Gehtland LM; Millington DS; Patel HS; Beckloff SE; Zimmerman SJ; Powell CM; Taylor JL
    JAMA Netw Open; 2020 Jan; 3(1):e1920356. PubMed ID: 32003821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients.
    Oussoren E; Keulemans J; van Diggelen OP; Oemardien LF; Timmermans RG; van der Ploeg AT; Ruijter GJ
    Mol Genet Metab; 2013 Aug; 109(4):377-81. PubMed ID: 23786846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of mucopolysaccharidosis I heterozygotes based on biochemical characteristics of L-iduronidase from dried blood spots.
    Campos D; Monaga M; González EC; Herrera D
    Clin Chim Acta; 2014 Mar; 430():24-7. PubMed ID: 24389097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I.
    Tomatsu S; Montaño AM; Oguma T; Dung VC; Oikawa H; de Carvalho TG; Gutiérrez ML; Yamaguchi S; Suzuki Y; Fukushi M; Sakura N; Barrera L; Kida K; Kubota M; Orii T
    J Inherit Metab Dis; 2010 Apr; 33(2):141-50. PubMed ID: 20162367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry.
    Scott CR; Elliott S; Buroker N; Thomas LI; Keutzer J; Glass M; Gelb MH; Turecek F
    J Pediatr; 2013 Aug; 163(2):498-503. PubMed ID: 23465405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass Spectrometry.
    Elliott S; Buroker N; Cournoyer JJ; Potier AM; Trometer JD; Elbin C; Schermer MJ; Kantola J; Boyce A; Turecek F; Gelb MH; Scott CR
    Mol Genet Metab; 2016 Aug; 118(4):304-9. PubMed ID: 27238910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses.
    Zhang H; Wood T; Young SP; Millington DS
    Mol Genet Metab; 2015 Feb; 114(2):123-8. PubMed ID: 25458519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III.
    de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N
    Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.